Ultragenyx Pharmaceutical Inc.
HealthcareNASDAQ:RARE · NASDAQ Global Select
+$0.37 today
Vol 1.85M · Avg 1.81M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
718.8%
avg -22.1%
ROIC
-43.5%
avg -44.3%
ROA
-37.5%
avg -36.2%
Analysis
ROE is currently the strongest return metric at 718.8% versus its period average of -22.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Emil D. Kakkis | Founder, President, Chief Executive Officer & Director | $1.19M | — | 66 | $23,095.00 | 0.02% |
Erik Harris | Executive Vice President & Chief Commercial Officer | $925,255.00 | — | 56 | $118,410.00 | 0.12% |
John Richard Pinion | Chief Quality Operations Officer & Executive Vice President of Translational Sciences | $923,934.00 | — | 60 | $133,142.00 | 0.14% |
Eric Crombez | Chief Medical Officer & Executive Vice President | $882,356.00 | — | 53 | $111,189.00 | 0.11% |
Howard Horn | Executive Vice President of Corporate Strategy & Chief Financial Officer | $846,010.00 | — | 47 | $105,689.00 | 0.11% |
Karah Herdman Parschauer | Chief Legal Officer & Executive Vice President of Corporate Affairs | $819,872.00 | — | 48 | $95,715.00 | 0.10% |
Dennis Karl Huang | Chief Technical Operations Officer and Executive Vice President of Gene Therapy Operations | $331,330.00 | — | 61 | $79,936.00 | 0.08% |
Ernie W. Meyer | Chief Human Resources Officer & Executive Vice President | — | — | 61 | — | — |
Theodore A. Huizenga | Senior Vice President, Corporate Controller & Principal Accounting Officer | — | — | 55 | $68,911.00 | 0.07% |
Vimal Srivastava | Senior Vice President of Business Development & Alliance Management | — | — | 61 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
25
$3.69M
Net Sentiment
$3.69M
Net selling
Most Active
Horn Howard
10 transactions
1–10 of 25
Analysis
Insiders reported 0 buys worth $0.00 and 25 sells worth $3.69M over the last 12 months. That adds up to net selling of $3.69M. Horn Howard was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.15B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.47B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.25B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$4.84B
Celcuity Inc.
NASDAQ:CELC
$4.32B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.11B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Soleno Therapeutics, Inc.
SLNO
$2.76B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Ascentage Pharma Group International
NASDAQ:AAPG
$409.04M
Who manages RARE?
Ultragenyx Pharmaceutical Inc. (RARE) lists 10 active executives. The top listed executive is Emil D. Kakkis, Founder, President, Chief Executive Officer & Director.
Are RARE insiders buying or selling?
Recent insider activity shows net buying of $29.74M.
Explore More
Continue the stock analysis
Jump to another research area for this company.